Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Michael Craig; Wahid T Hanna; Fernando Cabanillas; Chien-Shing Chen; Sudha Parasuraman; Rachel Neuwirth; Owen A. O'Connor

doi:10.1182/blood.v116.21.2798.2798

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Michael Craig
, Wahid T Hanna
, Fernando Cabanillas
, Chien-Shing Chen
, Sudha Parasuraman
, Rachel Neuwirth
, Owen A. O'Connor

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	116
DOIs	https://doi.org/10.1182/blood.v116.21.2798.2798
State	Published - Nov 19 2010

Disciplines

Medicine and Health Sciences
Immunology and Infectious Disease

Access to Document

10.1182/blood.v116.21.2798.2798License: Unspecified

OpenUrl availability

Full text

Cite this

Craig, M., Hanna, W. T., Cabanillas, F., Chen, C.-S., Parasuraman, S., Neuwirth, R., & O'Connor, O. A. (2010). Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study. Blood, 116. https://doi.org/10.1182/blood.v116.21.2798.2798

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study. / Craig, Michael; Hanna, Wahid T; Cabanillas, Fernando et al.
In: Blood, Vol. 116, 19.11.2010.

Research output: Contribution to journal › Article › peer-review

Craig, M, Hanna, WT, Cabanillas, F, Chen, C-S, Parasuraman, S, Neuwirth, R & O'Connor, OA 2010, 'Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.', Blood, vol. 116. https://doi.org/10.1182/blood.v116.21.2798.2798

@article{d93c099a50ab4301b6ad70e5e7d5a021,

title = "Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.",

author = "Michael Craig and Hanna, \{Wahid T\} and Fernando Cabanillas and Chien-Shing Chen and Sudha Parasuraman and Rachel Neuwirth and O'Connor, \{Owen A.\}",

note = "Abstract. Abstract 2798Background:. Non-Hodgkin's lymphoma is the most common hematologic malignancy, with an estimated 65,000 new cases in the US in 2010",

year = "2010",

month = nov,

day = "19",

doi = "10.1182/blood.v116.21.2798.2798",

language = "American English",

volume = "116",

journal = "Blood",

}

TY - JOUR

T1 - Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

AU - Craig, Michael

AU - Hanna, Wahid T

AU - Cabanillas, Fernando

AU - Chen, Chien-Shing

AU - Parasuraman, Sudha

AU - Neuwirth, Rachel

AU - O'Connor, Owen A.

N1 - Abstract. Abstract 2798Background:. Non-Hodgkin's lymphoma is the most common hematologic malignancy, with an estimated 65,000 new cases in the US in 2010

PY - 2010/11/19

Y1 - 2010/11/19

UR - http://www.bloodjournal.org/content/116/21/2798.abstract

U2 - 10.1182/blood.v116.21.2798.2798

DO - 10.1182/blood.v116.21.2798.2798

M3 - Article

VL - 116

JO - Blood

JF - Blood

ER -

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this